Immunosuppressed retinitis, toxocariasis and neuroretinitis
Key Takeaways
Severe immune compromise can permit destructive retinitis with little vitreous inflammation.
CMV blood testing cannot replace retinal examination; systemic treatment addresses risks beyond the injected eye.
Distinguish immune recovery inflammation from active necrosis before adding steroids.
Toxocara granuloma and neuroretinitis require targeted differentials rather than diagnosis from exposure or a macular star alone.
Immune status changes both appearance and urgency
Retinitis in an immunosuppressed patient can progress rapidly with surprisingly little inflammation. Ask about HIV status and treatment, transplant medication, chemotherapy, systemic corticosteroids and other immunomodulators. A quiet anterior chamber does not exclude a destructive retinal infection. Examine both eyes and the full peripheral retina, and coordinate urgent care with infectious-disease or transplant specialists when indicated.
Describe lesion location, necrosis, haemorrhage, vascular involvement and vitreous reaction. Obtain targeted ocular sampling when the diagnosis is uncertain or a result will change care. Serum exposure antibodies, a negative blood viral load and a photograph alone each have limitations. Consider cytomegalovirus (CMV), herpes-family necrotizing retinitis, toxoplasmosis and fungal disease, as well as lymphoma and other masquerades.
CMV retinitis
CMV can produce haemorrhagic or granular necrotizing retinal lesions in severe immune compromise. Vitritis may be limited before immune recovery. Retinal examination is central; blood CMV results alone neither establish nor reliably exclude ocular disease. Ocular fluid polymerase chain reaction can assist atypical cases but must be interpreted alongside clinical findings.
Systemic anti-CMV treatment is important for ocular and extraocular disease, with selected intravitreal treatment for immediately sight-threatening lesions. Valganciclovir or ganciclovir pathways require renal adjustment and blood-count monitoring; foscarnet has renal and electrolyte risks. The route and regimen depend on lesion location, absorption, systemic disease and specialist review. Intravitreal therapy alone does not protect the other eye or treat systemic infection.
Coordinate antiretroviral treatment in HIV. After immune recovery, immune recovery uveitis may cause vitreous inflammation and macular oedema despite controlled retinitis. Distinguish this from active recurrent necrosis before treating with corticosteroids. Continue ophthalmic follow-up because detachment and relapse can occur even after improved systemic immunity. In the current NIH pathway, new floaters or visual change in an at-risk patient warrants urgent ophthalmic assessment.
Herpetic disease and limited inflammation
Acute retinal necrosis often includes peripheral necrosis, occlusive vasculopathy and marked inflammation. Progressive outer retinal necrosis classically occurs with profound immune compromise, may start with multifocal outer-retinal lesions and can have little vitritis. These descriptive patterns can overlap. A calm eye is not reassuring when the retina shows advancing necrosis.
Urgent antiviral therapy, ocular sampling where useful and close retinal monitoring are required. Retinal breaks and detachment are major complications. Prophylactic laser is an individualized adjunct in selected eyes with a suitable view; it is not a proven mandatory 360-degree step for every necrotizing retinitis. Avoid delaying antiviral treatment while waiting for every laboratory result or beginning steroid monotherapy for presumed inflammation.
Toxocariasis
Ocular toxocariasis can cause a posterior or peripheral granuloma, vitreous inflammation and tractional bands, often in a young patient. Differentiate it from retinoblastoma and other causes of leukocoria. Ask about relevant exposures, but a history of contact with animals is not diagnostic. Serum testing can support the assessment, while a negative result may not exclude localized ocular disease.
Control vision-threatening inflammation and assess traction and detachment. Antiparasitic treatment decisions are specialist-led and should account for the inflammatory response; surgery may be needed for structural complications. Do not turn a granuloma into an indication for intraocular tumour biopsy before retinoblastoma has been appropriately excluded. Amblyopia and refractive rehabilitation remain important after the active process is managed.
| Presentation | Differential priority | Diagnostic caution |
|---|---|---|
| Necrosis with little vitritis | CMV or severe-immunosuppression herpes disease | Quiet eye is not benign |
| Granuloma with traction in a child | Toxocariasis and tumour mimics | Exposure history is insufficient |
| Disc swelling followed by macular star | Neuroretinitis | Star may appear after the disc change |
| Persistent atypical vitreous cells | Infection or masquerade | Steroid response does not exclude lymphoma |
Neuroretinitis and Bartonella
Neuroretinitis combines optic-disc inflammation with a macular star of lipid exudates, often developing after the initial disc swelling. Bartonella henselae is an important cause, but syphilis, other infections and noninfectious disorders can produce the pattern. Ask about systemic symptoms and exposure, and use targeted testing. A macular star does not by itself prove cat-scratch disease.
Antimicrobial treatment is chosen according to cause, severity and immune status with appropriate specialist input. Distinguish neuroretinitis from demyelinating optic neuritis and from disc swelling caused by raised intracranial pressure. Severe hypertension can also produce disc and macular findings. Assess both systemic safety and visual recovery, and reconsider the diagnosis if the course is atypical.
Sources: NIH CMV opportunistic-infection guidance, reviewed March 2026 and EBO curriculum.
Sections you finish are checked off in the contents.